Newer approaches in the treatment of asthma

Abstract

Asthma is a worldwide public health problem. The most effective anti-asthmatic drugs - inhaled ?2-agonists and glucocorticoids controls asthma in about 90-95% of patients. However, severe glucocorticoid-dependent and resistant asthma presents a great clinical burden. Therefore, reducing glucocorticoids - related adverse effects using novel steroid-sparing agents is needed. Furthermore, the mechanisms involved in the persistence of inflammation are poorly understood and the reasons why some patients have severe life threatening asthma and others have very mild disease are still unknown. Although glucocorticoids effectively control the inflammatory process in asthma, they have little effect on the lower airway remodeling processes that appear to play a role in the pathophysiology of asthma. Several new drugs developed to target specific components of the inflammatory process in asthma [e.g. anti-IgE antibodies (omalizumab), cytokines and/or chemokines antagonists, immunomodulators, antagonists of adhesion molecules)], have not yet been proven to be particularly effective. Hence, considering the central role of T lymphocytes in the pathogenesis of asthma, drugs targeting disease-inducing Th2 cells are promising future therapeutic strategies. Some of these new anti-asthmatic treatment approaches may in the future not only control symptoms and modify the natural course of asthma, but also potentially prevent or cure the disease. Hence, the development of novel drugs may allow resolution of these changes. [Int J Basic Clin Pharmacol 2012; 1(2.000): 67-71

Synthesis, characterization and evaluation of the suppression of insulin resistance in Type-II diabetes mellitus animals by treatment with metal complex

“…Diabetes is the most common disease as far as metabolic disorder is concerned, its incidence in the year 2010 was 210 million and by 2025 it is proposed to increase to 300 million (Patel et al, 2013). Diabetes mellitus is divided into two types, Type-I and Type-II.…”

“…Nowadays researchers are focusing on target based treatment. Piroxicam proliferative activated receptors, glucagon like peptide hormone β3-Adenoreceptor agonist, DPP-IV inhibitors, α-lipoic acid, liver selective glucocorticoid antagonist, PTB-1B inhibitors, glycogen synthase kinase involved in glycogen metabolism, fructose-1, 6-biphosphate as a therapeutic target for Type-II diabetes are the new approaches in the treatment of diabetes mellitus (Patel et al, 2013).…”

Antidiabetic Properties of Thirteen Local Medicinal Plants in Nigeria, a Review

“…It is estimated that the number will increase to over 366 million by 2030 and that large increase will occur in developing countries, especially in people aged between 45 and 64 years. [3,4,5] Currently many countries face large increases in the number of people suffering from diabetes. [4] Different types of reported diabetes mellitus can be classified under following two categories:…”

“…[3,4,5] Currently many countries face large increases in the number of people suffering from diabetes. [4] Different types of reported diabetes mellitus can be classified under following two categories:…”

Morphological and Functional Changes of Masticatory Muscle Neuromuscular Junctions in the Later Periods of Streptozotocin Diabetes Mellitus Course

“…Adaptation changes in neuromuscular junctions (NMJ) in this position are associated with lengthening and increasing the number of terminal branches of the motor axon [6]. At the same time, the number of terminal neurleulocytes, the cortical nuclei and the area of NMJ decreases [18]. According to some authors [17], the qualitative features of the restructuring of NMJ in the experimental streptotrozine DM should lead to the formation of unusual structures of active zones and a new histochemical characterization of the totality of NMJ in skeletal muscles at CD.…”